Pharmacy Firm's $7B Deal: Experimental Drug Sold to Roche
TL;DR Summary
Roivant Sciences, a pharmaceutical company founded by Vivek Ramaswamy, is in talks to sell an experimental drug for the treatment of stomach diseases in a deal that could be valued at over $7 billion. The drug, RVT-3101, is currently in Phase 3 testing and has shown positive results. Roivant acquired the drug from Pfizer and formed a subsidiary called Telavant to fund its development. Roche, the fifth-largest pharmaceutical company globally, is reportedly ready to pay billions to secure the rights to the drug. If the deal goes through, it would be one of the biggest moves by Roche since its new CEO took over.
Topics:business#acquisition#business#drug-development#pharmaceutical-industry#roivant-sciences#vivek-ramaswamy
- Vivek Ramaswamy's pharmacy firm to sell experimental drug in $7B deal New York Post
- Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion - WSJ The Wall Street Journal
- Roche lining up potential $7B Roivant licensing deal to join Merck in bowel disease race: WSJ FierceBiotech
- Roche Could Take A Page Out Of Merck's Playbook. Why Another Stock Surged. Investor's Business Daily
- Roivant in talks to sell bowel-disease drug to Roche in over $7 billion deal, Wall Street Journal reports Reuters.com
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
80%
519 → 104 words
Want the full story? Read the original article
Read on New York Post